The Comparison of AMD Treatments Trials 5-year outcomes21 showed that vision gains that were made during the first 2 years of treatment were not maintained at 5 years follow-up; however, 50% of eyes had VA of 20/40 or better, solidifying anti-VEGF therapy as a major long-term therapeutic advance for nAMD. This evidence concerns the gene VEGFA and age-related macular degeneration.